title: Clusterin confers gemcitabine resistance in pancreatic cancer.
abstract: OBJECTIVE
  To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells.
  
  
  METHODS
  Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds, and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot and PT-PCR. The correlation between clusterin expression level and gmcitabine IC50 in pancreatic cancer cell lines was evaluated. The effect of an antisense oligonucleotide (ASO) against clusterin (ASO-CLU) [corrected] on gmcitabine resistance was evaluated by MTT assays. Xenograft model was used to demonstrate tumor growth.
  
  
  RESULTS
  Pancreatic cancer tissues expressed significantly higher levels of clusterin than did normal pancreatic tissues (P < 0.01). Clusterin expression levels were correlated with gmcitabine resistance in pancreatic cancer cell lines, and ASO-CLU [corrected] significantly decreased BxPc-3 cells resistance to gmcitabine (P < 0.01). In vivo systemic administration of AS clusterin and gmcitabine significantly decreased the s.c. BxPC-3 tumor volume compared with mismatch control ODN plus gmcitabine.
  
  
  CONCLUSIONS
  Our finding that clusterin expression was significantly higher in pancreatic cancer than in normal pancreatic tissues suggests that clusterin may confer gmcitabine resistance in pancreatic cancer cells.
authors: Affiliated Hospital of Medical College, QingDao University, RP China.
authors: Qingfeng
authors: Q
authors: Chen
authors: Zhengkun
authors: Z
authors: Wang
authors: Kejun
authors: K
authors: Zhang
authors: Xiaoyi
authors: X
authors: Liu
authors: Weihong
authors: W
authors: Cao
authors: Lei
authors: L
authors: Zhang
authors: Shuhua
authors: S
authors: Zhang
authors: Bomin
authors: B
authors: Yan
authors: Yaoguang
authors: Y
authors: Wang
authors: Chunping
authors: C
authors: Xia
references: Biol Reprod. 1983 Jun;28(5):1173-88
references: 6871313
references: Int J Biochem Cell Biol. 2002 Nov;34(11):1430-48
references: 12200037
references: Pancreas. 2002 Oct;25(3):234-8
references: 12370533
references: Nat Cell Biol. 2005 Sep;7(9):909-15
references: 16113678
references: Biochem Biophys Res Commun. 2007 May 4;356(2):431-7
references: 17359935
references: Kidney Int. 1998 Jun;53(6):1647-53
references: 9607196
references: Exp Cell Res. 1996 Jan 10;222(1):54-60
references: 8549673
references: Mol Cancer Ther. 2004 Mar;3(3):223-32
references: 15026542
references: BJU Int. 2008 Aug;102(3):389-97
references: 18336596
references: Cancer Res. 2004 Mar 1;64(5):1834-42
references: 14996747
references: Int J Cancer. 2007 Feb 1;120(3):611-22
references: 17096323
references: Am J Pathol. 2000 Aug;157(2):393-9
references: 10934144
references: BJU Int. 2009 Feb;103(3):384-90
references: 19007378
references: J Urol. 2002 May;167(5):2203-8
references: 11956479
references: Neoplasia. 2001 Jul-Aug;3(4):360-7
references: 11571636
references: Cancer Lett. 2004 Jan 20;203(2):155-61
references: 14732223
references: Mol Cancer Ther. 2005 Dec;4(12):1837-49
references: 16373699
references: J Urol. 2004 Jun;171(6 Pt 1):2477-81
references: 15126879
references: Expert Rev Anticancer Ther. 2010 Oct;10(10):1647-61
references: 20942635
references: Cell Death Differ. 2006 Jan;13(1):12-9
references: 16179938
references: Cancer Res. 1991 Jan 1;51(1):162-6
references: 1899037
references: Adv Cancer Res. 2009;105:77-92
references: 19879424
references: Lab Invest. 2011 Mar;91(3):426-38
references: 21283078
references: Urology. 2002 Jan;59(1):150-4
references: 11796313
references: J Biol Chem. 2003 Mar 28;278(13):11590-600
references: 12551933
references: Oncogene. 2003 May 22;22(21):3243-51
references: 12761494
references: Int J Biochem Cell Biol. 1995 Jul;27(7):633-45
references: 7648419